EPP Life Sciences Pricing Forum 2025
CONTENT HUB
Access exclusive, industry-led insights for free! Complete the form once to unlock all current and future content – no repeated sign-ups needed
Q2 2025 Drug Contracting Trends Report:
The Great GLP-1 Rush
Lyfegen’s latest report offers fresh insights into how payers and pharma are tackling access and affordability challenges—especially amid rising demand for GLP-1 therapies and obesity treatments.
Built on 8,000+ real-world agreements from 25 countries, the report highlights how outcome guarantees, budget caps, and conditional reimbursement models are shaping drug pricing strategies for high-cost therapies like gene therapies and GLP-1s.
Key takeaways include:
- Emerging models to manage clinical and financial risk
- Real-world contracting trends and regional shifts across Europe, North America, and Asia
- Strategic recommendations for pharma, including value segmentation, long-term outcomes planning, and reframing obesity as a chronic condition
The report offers a global view of the evolving market access landscape—and how smarter strategies are unlocking better drug access in 2025 and beyond.
Pricing Insights – How to Use Data to Inform Pricing Strategy
In this keynote, Ulrik Haagen Panton, VP Global Pricing at Novo Nordisk, explores how data-driven insights can shape smarter pricing strategies. Gain a clear understanding of the value of pricing analytics, its role in execution, and the key challenges and opportunities in applying it across pharma, biotech, and MedTech.